High levels of interleukin-6 in the exhaled breath condensate of patients with COPD

Respiratory Medicine

Volumn 97, Issue 12, 2003, Pages 1299-1302

  Bucchioni, Enrica ^a   Kharitonov, Sergei A ^b   Allegra, Luigi ^a   Barnes, Peter J ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Exhaled breath condensate; Interleukin 6

Indexed keywords

INTERLEUKIN 6;

ADULT; AGE; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; EXHALATION; FEMALE; FIBROBLAST; HUMAN; KERATINOCYTE; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SMOKING; STROMA CELL; T LYMPHOCYTE;

EID: 0346901131     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.07.008     Document Type: Article

References (13)

1. American Thoracic Society. Standards for the diagnosis, care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:s77-s120.
2. Yasuda N, Gotoh K, Minatoguchi S, et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998;92:993-9.
3. Park CS, Chung SW, Ki SY, et al. Increased levels of interleukin-6 are associated with lymphocitosis in bronchoalveolar lavage fluids of idiopathic non-specific interstitial pneumonia. Am J Resp Crit Care Med 2000;162:1162-8.
4. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55(7):629-30.
5. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Resp Crit Care Med 2001;163:1693-722.
6. Von Pohle WR, Anholm JD, McMillan J. Carbon dioxide and oxygen partial pressure in expiratory water condensate are equivalent to mixed expired carbon dioxide and oxygen. Chest 1992;101:1601-4.
7. Quarner PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Official statement of the European Respiratory Society: lung volume and forced expiratory flow. Eur Resp J 1993;6(Suppl. 16):5-40.
8. British Thoracic Society. BTS guidelines for the management of chronic pulmonary disease. Thorax 1997;52(Suppl. 59):s4-s10.
9. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a biomarker of oxidative stress, in exhaled condensate of asthma patients. Am J Resp Crit Care Med 1999;160:216-20.
10. Bland JM, Altman DG. Statistics notes: measurement error. Br Med J 1996;313:744.
11. Yokoyama A, Kohono N, Hirasawa Y, et al. Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol 1995;100:325-9.
12. Dowlati A, Levitan N, Remick SC. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med 1999;134(4):405-9.
13. Dekhuijen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patient with stable and unstable chronic obstructive pulmonary disease. Am J Res Crit Care Med 1996;154:813-6.